A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy and safety of conversion treatment of
Hepatic Arterial Infusion Chemotherapy combined with Camrelizumab and Apatinib for unresected
hepatocellular carcinoma.